It probably takes a long time for other drug companies to look at alternative (presumably simpler and safer) long-acting method. Today's saga of "Novo Nordisk shares fall after FDA raises heart concerns with long-acting insulin" may hasten other drug companies besides MRK to try PBTH's CTP methods of making long-acting proteins.
The potential heart side effect may not have any connection with NVO drug. "A panel of federal health advisers recommended Thursday that the government approve an experimental, long-acting diabetes drug from Danish drugmaker Novo Nordisk...The group's endorsement came despite some concern about potential heart safety side effects with the drug"
Yep, that is a pattern with these guys. All they need to do is simply say everything is on track and they can't even give us that. They would rather sit back and watch the price tank and blame it on someone else. I am confident that is why the report was issued as it was. All the rest maintain their targets. The worst part is they still don't get that lack of communication is 90% of their problem.